| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $219.1M | — | +1.9% |
| R&D Expense | $6.2M | — | +14.0% |
| SG&A Expense | $45.8M | — | +28.0% |
| Operating Income | $50.7M | — | -16.0% |
| Pre-tax Income | $31.2M | — | -15.5% |
| Income Tax | $8.8M | — | +51.7% |
| Net Income | $21.6M | — | -29.0% |
| EPS (Basic) | $0.20 | — | -28.6% |
| EPS (Diluted) | $0.20 | — | -25.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $111.6M | +15.7% | +119.3% |
| Accounts Receivable | $104.4M | +11.3% | -1.0% |
| Inventory | $69.7M | -5.6% | -13.7% |
| Current Assets | $309.1M | +11.8% | +20.4% |
| Total Assets | $2.53B | +0.1% | -3.0% |
| Current Liabilities | $108.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $71.6M | — | +17.2% |
| Capital Expenditures | $30.0M | — | +22.0% |
| Investing Cash Flow | -$30.0M | — | -22.0% |
| Financing Cash Flow | -$26.3M | — | +67.5% |
| Free Cash Flow | $41.7M | — | +14.0% |
| -16.1% |
| Total Liabilities | $2.06B | -0.2% | -1.3% |
| Stockholders' Equity | $468.4M | +1.2% | -9.7% |